Photocure ASA (PHS) Price & Analysis

1 Followers

PHS Stock Chart & Stats

€4.92

-€0.05(-0.98%)

At close: Jul 24 4:00 PM EDT

€4.92

-€0.05(-0.98%)

Day’s Range― - ―

52-Week Range€4.28 - €6.71

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€119.77M

Enterprise Value€1.37B

Total Cash (Recent Filing)€259.54M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)25.2

Beta0.26

Next Earnings

Feb 24, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.02

Shares Outstanding27,120,820

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Photocure ASA News

Photocure ASA Earnings Call Signals Ambitious Growth

Photocure ASA (($NO:PHO)) has held its Q3 earnings call. Read on for the main highlights of the call....

3d ago

Photocure lifts 2026 growth outlook as it builds broader bladder cancer diagnostics platform

Photocure ASA ( ($PHCUF) ) has issued an update. Photocure reported third‑quarter 2026 Hexvix/Cysview revenues of NOK 134.2...

4d ago

Photocure Grants Share Options to New CFO Under Long-Term Incentive Plan

The latest announcement is out from Photocure ASA ( ($PHCUF) ). Photocure ASA has granted 200,000 share options...

4d ago

Photocure Strengthens Executive Team With Appointment of Veteran CFO

The latest update is out from Photocure ASA ( ($PHCUF) ). Photocure ASA has appointed Dennis Camporeale as...

9d ago

Photocure Sets Date for Third-Quarter 2026 Results and Investor Webcast

An update from Photocure ASA ( ($PHCUF) ) is now available. Photocure ASA will publish its third-quarter 2026...

11d ago

FDA Move to Ease Regulatory Pathway Seen as Catalyst for Photocure’s Bladder Cancer Technology

The latest announcement is out from Photocure ASA ( ($PHCUF) ). Photocure ASA reported that the U.S. Food...

3M ago

Photocure Study Finds Blue Light Cystoscopy Boosts Bladder Cancer Detection Without Raising Costs

An announcement from Photocure ASA ( ($PHCUF) ) is now available. Photocure ASA reported new real-world evidence showing...

3M ago

Photocure Board Members Boost Shareholdings, Signaling Confidence in Uro-Oncology Strategy

Photocure ASA ( ($PHCUF) ) has provided an update. Board chairman Dylan Hallerberg and board member Neal Shore...

3M ago

Photocure escalates arbitration in Cevira milestone dispute with Asieris

The latest announcement is out from Photocure ASA ( ($PHCUF) ). Photocure ASA is a Norway-based commercial diagnostic...

3M ago

Photocure ASA Earnings Call Signals Growth-Driven Strategy

Photocure ASA (($NO:PHO)) has held its Q2 earnings call. Read on for the main highlights of the call....

3M ago

PHS FAQ

What was Photocure ASA’s price range in the past 12 months?

Photocure ASA lowest stock price was €4.28 and its highest was €6.71 in the past 12 months.

What is Photocure ASA’s market cap?

Photocure ASA’s market cap is €119.77M.

When is Photocure ASA’s upcoming earnings report date?

Photocure ASA’s upcoming earnings report date is Feb 24, 2027 which is in 116 days.

How were Photocure ASA’s earnings last quarter?

Photocure ASA released its earnings results on Oct 28, 2026. The company reported -€0.094 earnings per share for the quarter.

Is Photocure ASA overvalued?

According to Wall Street analysts Photocure ASA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Photocure ASA pay dividends?

Photocure ASA does not currently pay dividends.

What is Photocure ASA’s EPS estimate?

Photocure ASA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Photocure ASA have?

Photocure ASA has 27,120,820 shares outstanding.

What happened to Photocure ASA’s price movement after its last earnings report?

Photocure ASA reported an EPS of -€0.094 in its last earnings report. Following the earnings report the stock price went up 1.512%.

Which hedge fund is a major shareholder of Photocure ASA?

Currently, no hedge funds are holding shares in DE:PHS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Photocure ASA

Photocure ASA is a specialized pharmaceutical enterprise focused on the development, manufacturing, commercialization, and distribution of medicinal products. Its operational footprint extends across multiple European nations, including the Nordic region, Germany, France, Austria, the United Kingdom, the Netherlands, and Italy, in addition to the United States. The company's primary offering, Hexvix/Cysview, aids in the identification and ongoing management of bladder cancer. Moreover, Photocure is actively progressing Cevira, a therapeutic agent in development targeting human papilloma virus (HPV) infections and pre-cancerous lesions of the cervix. The firm distributes its products to pharmaceutical wholesalers, pharmacies, and healthcare institutions through collaborative licensing arrangements. Founded in 1993, Photocure ASA maintains its corporate headquarters in Oslo, Norway.

Photocure ASA (PHS) Earnings & Revenues

Historic Earnings Reports

PHS Company Deck

PHS Earnings Call

Q3 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call was predominantly positive. Photocure reported 7% constant-currency product revenue growth, strong unit and active-account expansion, improving adjusted EBITDA, continued European and North American momentum, progress on FDA reclassification and OEM access, and multiple long-term growth initiatives. The main negatives were foreign-exchange pressure, a quarterly net loss, higher operating expenses, pending CMS and FDA decisions, expected near-term AssureMDx operating losses, and uncertainty around potential generic competition. Management nevertheless raised 2026 guidance and reiterated substantial long-term growth and margin targets.View all DE:PHS earnings summaries